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4 Abstract 
6 Background 
7 
8 Communal online folk pharmacology fuels the drive for short cuts in attaining muscle 
9 enhancement, fat loss, and youthful skin. 
11 Objectives 
12 
13 The study used ‘netnography’ to explore female use of CJC-1295, a synthetic growth 
14 hormone analogue from the perspectives contained in internet forum activity. 
16 Methods 
17 
18 A  systematic  internet  search  was  conducted  using  variation  of  the  term  ‘CJC-1295;  and 
19 combined  with  ‘forum’.  96  hits  related  to  bodybuilding  websites  where  CJC-1295  was 
21 mentioned. Following application of exclusion criteria to confine to female use and evidence 
22 
23 of forum activity, 9 sites remained. These were searched internally for reference to CJC- 
24 1295. 23 discussion threads relating to female use of CJC-1295 formed the end data set, and 
26 analysed using the Empirical Phenomenological Psychological method. 
27 
28 Results 
29 Forum users appeared well versed and experienced in the poly use of performance and image 
31 drug supplementation. Choice to use CJC-1295 centred on weight loss, muscle enhancement, 
32 
33 youthful skin, improved sleep and injury healing. Concerns were described relating to female 
34 consequences of use given gender variations in growth hormone pulses affecting estimation 
36 of dosage, cycling and long term consequences. 
37 
38 Conclusions 
39 Public health interventions should consider female self-medicating use of synthetic growth 
41 hormone within a repertoire of product supplementation, and related adverse health 
42 
43 consequences. 
44 
45 
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4 Introduction 
6 Widespread availability and growing prevalence in the use of image and performance 
7 
8 enhancement drugs within mainstream fitness groups has contributed to an emergent public 
9 health issue (Christiansen, 2009; Evans-Brown et al., 2012; Ip et al., 2012; Pope et al., 2014). 
11 Blurring between self-medication, medical treatment and augmentation of performance and 
12 
13 appearance is increasingly evident in contemporary society (Dodge & Hoaglund, 2011). 
14 Muscle enhancing supplements are most commonly used, with users commonly engaging in 
16 poly pharmacy by ingesting drugs designed to stimulate testosterone or growth hormone 
17 
18 secretion (i.e. clomiphene, gamma hydroxybutyrate, levodopa) with other hormones (i.e. 
19 thyroid hormones, human chorionic gonadotropin, insulin-like growth factor-1), ergogenic 
21 drugs (amphetamine, caffeine, pseudoephedrine, ephedrine, clenbuterol), drugs for weight or 
22 
23 fluid loss (diuretics, laxatives), other agents (erythropoietin, tamoxifen, danazol, yohimbine, 
24 2,4-dinitrophenol) and illicit drugs of abuse (cannabis, opiates, cocaine) (Gruber & Pope, 
26 2000; Kanayama et al., 2001; Kanayama et al., 2010; Kanayama & Pope, 2012; Ip et al., 
27 
28 2012). Rising use of enhancement supplements sold over the counter in commercial health 
29 club users is observed (Muller et al., 2009). Consequences of use centre on harms associated 
31 with use of untested and unregulated substances obtained on the illicit market, medical and 
32 
33 psychiatric adverse effects, dependence syndrome and fatalities (Thiblin et al., 2009; 
34 Kanayama & Pope, 2012; Ip et al., 2012; Pope et al., 2014). 
36 
37  
38 Focus and preoccupation on body image is increasingly common for both genders in recent 
39 decades (Cash & Pruzinsky, 2002). Use of enhancement drug supplements is reportedly 
41 widespread amongst athletes at all ages and competitive levels (Calfee & Fadale, 2006). 
42 
43 Some studies suggest men are more willing to use enhancement drugs than women (Møldrup 
44 & Hansen 2006; Breivik et al., 2009). Prevalence of muscle enhancing supplement use is 
46 mostly male, but more recently among female athletes (Thiblin et al., 2009) and elite female 
47 
48 bodybuilders (Gruber & Pope, 2000; Evans-Brown & McVeigh 2009). Drug supplementation 
49 differs per gender, with females more likely to report use of ephedrine, human growth 
51 hormone, human chorionic gonadotropin and clenbuterol as opposed to muscle enhancing 
52 
53 supplements (Brill & Keane, 1994; Jespersen, 2012). Recent commentaries have underscored 
54 the need to recognise that use of enhancement drug supplements can occur in other segments 
56 of the fitness population, and more recently among women who exercise (Jespersen, 2012). 
57 
58 Of interest for this study is that changing social perspectives of the ideal female physique are 
Page 3 of 29 Substance Use and Misuse Netnography of female use of the synthetic growth hormone CJC- 
  1295: Pulses and Potions.  1 2 
3 
57 
58 
59 
60 3 
URL: http:/mc.manuscriptcentral.com/lsum eincert@gmail.com 
 
 
5 
10 
20 
25 
30 
35 
40 
45 
50 
55 
4 evident  in recent  times. Popularity of  the  female body ideal from  slim  (Brumberg, 1998) has 
6 shifted toward that of a lean, athletic, fit and strong physique with masculine characteristics 
7 
8 (Grogan, 2006). This shift has potentially contributed to the female adoption of specific male 
9 characteristic behaviours relating to drug supplementation and fitness training (Field et al., 
11 2005; Muller et al., 2009). Concerns are evident with regard to the lack of female reporting 
12 
13 and hidden nature of female enhancement drug use (Kanayama et al., 2010). 
14 
15 
16 Growth Hormone and CJC-1295 
17 
18 Human growth hormone is a naturally occurring peptide hormone which maintains body 
19 composition, and improves physical performance, cardiovascular health and wellbeing in 
21 humans (Graham et al., 2008a; Graham et al., 2008b; Olshansky & Perls 2008; Graham et al., 
22 
23 2009; Erotokritou-Mulligan et al., 2011). It is one of the oldest and popular anti-aging 
24 treatments in animal models (Rudman et al., 1990; Liang et al., 2003; Al-Regaiey et al., 
26 2005; Sun et al., 2005) despite concerns for adverse side effects (Liu et al., 2007; Ayuk & 
27 
28 Sheppard, 2008; Brennan et al., 2010) and reviews that supplementation does not 
29 significantly increase muscle strength or aerobic capacity in either health subjects (Liu et al., 
31 2008) or non-human growth hormone deficient subjects (Gibney et al., 2007; Ehrnborg & 
32 
33 Rosen, 2008; Graham et al., 2009). Clinical studies observe its limited properties to promote 
34 muscle growth in healthy active subjects with outcomes complicated by issues in targeting 
36 appropriate dosage and cardiovascular and metabolic consequences (Crist et al., 1988; 
37 
38 Deyssig  et  al.,  1993;  Wallace  et  al.,  1999;  Berggren  et  al.,  2005;  Ehrnborg  et  al., 2005). 
39 However,  in  combination  with  anabolic  steroids or  on  cessation of  anabolic  steroid  use, it 
41 may incur these effects (Gibney et al., 2007; Ehrnborg & Rosen, 2008; Graham et al., 2009). 
42 
43 
44 Human  growth  hormone  was  once  abused  solely  by  elite  athletes  (Salomon  et  al., 1989). 
46 Illicit use is rising in athletes striving to improve physical performance with demand fuelled 
47 
48 by internet availability of new, cheap and potent synthetic growth hormone releasing 
49 hormone analogues (Brennan et al., 2010; Cai et al., 2014). This rise in synthetic peptide drug 
51 manufacture, often marketed without prior clinical trials (Henninge et al., 2010) occurs in 
52 
53 correspondence with development of new detection methods in sport (Saugy et al., 2006; 
54 Sackmann-Sala et al., 2009; Bidlingmaier & Strasburger, 2010; Thomas et al., 2012). Illicit 
56 use has also displaced into repertoires of poly pharmaceutical and illicit drug use in 
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4 bodybuilding and weight lifting groups (Rickert et al., 1992; Gruber & Pope, 2000; 
6 Kanayama et al., 2003; Baker et al., 2006; Skarberg et al., 2009; Brennan et al., 2010). 
7 
8 
9 Of interest for this study is the popular and potent long-acting synthetic analogue is CJC- 
11 1295.  It  is  a  tetra  substituted  30-amino  acid  peptide  hormone  originally  manufactured by 
12 
13 Conju Chem, a Canadian biotechnology company. Similar to other peptides sold over the 
14 internet (Van Hout, 2014), CJC-1925 is a sterile, non-pyrogenic, white lyophilized powder 
16 for administration via subcutaneous or intramuscular injection at doses of around 100mcg per 
17 
18 injection, and after reconstitution with sterile water. Websites purport that CJC-1295 
19 contributes to an enhanced immune system, improved sleep, boosting of protein synthesis, 
21 with mild side effects including flushing, water retention, and in some cases insomnia. In 
22 
23 contrast to natural growth hormone releasing hormone which has a half-life of approximately 
24 7 minutes, CJC-1296 has a longer half-life of 6-8 days (Jetté et al., 2005; Alba et al., 2006; 
26 Teichman et al., 2006; Chapter et al., 2010; Baumann, 2012). CJC-1295 causes sustained, 
27 
28 pulsatile human growth hormone secretion and increased insulin-like growth levels for 
29 several days after one single dose (Chapter et al., 2010). The product is marketed with and 
31 without drug affinity complex (DAC) technology, which optimises this longer half-life and 
32 
33 resultant therapeutic window (Teichman et al., 2006). CJC-1295’s long half-life is appealing 
34 to users by facilitating a 7 day dosage schedule (Ionescu & Frohlman, 2006; Teichman et al., 
36 2006; Chapter et al., 2010). 
37 
38  
39 The  natural  history  effects  of  CJC-1295  in  human  subjects  are  for  the  most  part  largely 
41 unknown,  with study effects centring on  secretion  of  growth  hormone, frequency  of adverse 
42 
43 consequences and effects of cumulative dosage (Jette et al., 2005; Ionescu & Frohman, 2006; 
44 Teichman et al., 2006; Alba et al., 2006; Sackmann–Sala et al., 2009; Evans-Brown et al., 
46 2012). It has potential for abuse risk for performance enhancement purposes (Baumann, 
47 
48 2012). Decisions to use centre on its anti-aging properties, promotion of lipolysis with fat loss 
49 in the stomach area, muscle growth, increased strength, improved skin tone with reduced 
51 wrinkling, improved slow wave sleep, energising effect, stronger bones, promotion of 
52 
53 regrowth of internal atrophied organs and connective tissues, and improvements in immune 
54 systems (Saugy, et al., 2006; Evans-Brown et al., 2012). Health risks of CJC-1295 include 
56 cardiomyopathy, menstrual irregularities, osteoporosis, impotence, potential blood borne 
57 
58 virus transmission in shared injection practices, and premature mortality from cardiovascular 
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4 diseases  (Saugy,  et  al.,  2006).  It  is  readily available  via  sub-cultural  and  internet sourcing 
6 routes  (Thomas  et  al.,  2010)  and  is  widely  purported  as  ancillary  supplement  within 
7 
8 bodybuilding communities (Henninge et al., 2010). 
9 
10 
11 Rationale 
12 
13 Information on enhancement drug use motives, sourcing, practices and protocols for use are 
14 available via sub-cultural guides (Gallaway, 1997; Roberts & Clapp, 2006; Llewellyn, 2009), 
16 and from internet sites promoting forum exchange of knowledge, influence around products 
17 
18 and sourcing routes (Kanayama et al., 2010). Given the potency of the internet in hosting 
19 forum discussion, promoting indigenous harm reduction, social reinforcement of 
21 consumption and product knowledge exchange between illicit enhancement drug users 
22 
23 (Smith & Stewart, 2012; Van Hout, 2014), the study used ‘netnography’ (Kozinets, 2002) to 
24 explore female use of CJC-1295 from the perspectives disclosed in publically available 
26 internet forum activity. This novel internet methodology adapts ethnographic research 
27 
28 techniques to the study of communities emerging through cyber mediated communication. 
29 The underpinning purpose of the study was to yield unique insight into female online folk 
31 pharmacology relating to CJC-1295 within asynchronous interactions in diverse forum 
32 
33 threads  and  discussions  between  unconnected  users  (Hsiung,  2000).  The  study  aimed  to 
34 provide  greater  understanding of  the  essence of  CJC-1295  experiences within  the reflective 
36 life world of female users and in the absence of preconceived hypotheses or generalizations 
37 
38 (Wertz, 2005). 
39 
40 
41 Methods 
42 
43 Dedicated online research methodologies are increasingly used to uncover emergent drug 
44 trend phenomena by virtue of systematic gathering of textual data based on passive 
46 monitoring and textual qualitative analysis of publically available user postings in drug forum 
47 
48 discussions (Kozinets, 2002; Miller & Sønderlund, 2010; Van Hout, 2014). The aim of the 
49 study was to explore and describe CJC-1295 female user decision making processes, 
51 practices and side effect phenomena as per their subjective interpretations of their 
52 
53 experiences and cognisant of their realities (Patton, 2002). In accordance with designated 
54 protocols for online research, a series of public body building forums were scrutinised with 
56 researchers maintaining observational status. Sampling of forum activity by female users of 
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4 CJC-1295 was grounded in Kozinet’s criteria relating to scale, interactivity and 
6 heterogeneity. 
7 
8 
9 A  systematic  internet  search  was  performed  on  Google  Insights  for  Search,  Google  and 
11 Yahoo  by using  specific  key  words;  ‘CJC-1295,  ‘CJC  1295  ‘and  in  combination  with the 
12 
13 word ‘forum’. The searches generated 96 hits relating to sites where the term CJC-1295 was 
14 mentioned. The first 50 hits of the searches were examined more closely, with sites excluded 
16 if not defined as a bodybuilding website1, and if not hosting forum discussions. A total of 38 
17 
18 sites hosting forum activity around CJC-1295 use remained. Of these 38 sites, a further 29 
19 were excluded when no dedicated female section was located on the website. Subsequently 
21 the remaining 9 sites were searched systematically for reference to CJC-1295 by utilizing the 
22 
23 site’s internal search engine, and using the term ‘CJC-1295’. This search ran until no more 
24 data could be located on the female use of CJC-1295, and generated 37 identified threads 
26 relating to female use and interest in CJC-1295. Following exclusion of duplicate threads and 
27 
28 male discussions, 23 discussion threads remained. 59 distinct user pseudonyms were recorded 
29 in the data set. See Table 1. 
31 
32 
33 Insert Table 1 here. 
34 
35 
36 The textual data was transferred to a Word document with the final data set of 14621 words 
37 
38 stored in an online, password-protected computer. Even though the information is widely 
39 available on public website, the participants’ anonymity was protected by removal of URLs 
41 and personal identifiers (Wilkinson & Thelwall, 2011). The dataset was analysed in an open, 
42 
43 unbiased and careful manner by using the Empirical Phenomenological Psychological (EPP) 
44 five step method (Karlsson, 1995) which is underpinned by Husserl’s (1970) phenomenology 
46 theory. This approach has strong similarities with Giorgi’s (2000) principles and facilitates 
47 
48 interpretation of meaning of lived phenomena. The EPP method was employed to carefully 
49 collect qualitative information in an open and unbiased manner, cognizant of optimising 
51 validity in describing subjective female experiences of the CJC-1296 phenomenon, as so 
52 
53 called life world experiences. The researchers strove to ensure that participant reporting of 
54 
55 
56 
57    
58 1 A site with forum dedicated to bodybuilding, weight loss, exercise, and overall healthy living. 
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data set, by checking the category was maintained, and consideration  of  specific  
characteristics and similarities in the female CJC-1295 phenomena. 
5 
10 
15 
20 
25 
35 
55 
4 the CJC-1295 experience was undistorted by any pre understanding of the researchers in the 
6 initial steps of analysis. 
7 
8 
9 The following key steps were followed and adapted from EPP protocols employed in 
11 previous netnographic work on illicit substances (Van Hout, 2014): 
12 
13 Step 1. Data was read three times in order to familiarize with the topic of female use of CJC- 
14 1295, and create an unbiased overview without any specific hypothesis. Theoretical reflection 
16 was withheld. 
17 
18 Step 2. Data was divided into smaller meaning units (MU), without regard to recorded 
19 syntax, and each time a new meaning, focus or topic on female use of CJC-1295 occurred in 
21 the text. MU consisted of whole paragraphs to single words, with the text marked each time a 
22 
23 shift in meaning took place. 
24 Step 3. MU were restated by researchers in order to present the significant and implicit 
26 
27 
28 
29 
30 
31 
32 
33 
34 Step 5. Categories were subsequently situated within more general themes, in order to raise 
36 the  level  of  abstraction  through  identifiable  patterns  within  related categories.  Five themes 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 Results 
47 
48 Five themes emerged which are presented below with illustrative quotations. 
49 
50 
51 Female interest in CJC-1295 and informed decision-making 
52 
53 Female forum activity reported on choices to use CJC-1295 as centring on its properties to 
54 stimulate  fat  loss,  enhance  muscle  tone,  improve  sleep,  joint  mobility,  aid  in  healing and 
56 improve skin quality and texture. 
with 47 categories were generated. See Table 2. Steps 3 to 5 were influenced by the 
reflections of Giorgi (2000). 
Insert Table 2 here 
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4 ‘I am totally new at this, never tried anything before. I am trying to lose weight 
6 and nothing seems to work, I need something to keep me a boost’. 
7 
8 The majority of interested users posted queries on CJC-1295 on foot of media articles and 
9 both online and real peer feedback. 
11 ‘Best friend was thinking about using it, and I was reading an article about a girl 
12 
13 who took it. It says she lost a good amount of weight and has kept it off. It just did 
14 not say any side effects, so I wanted to find out some more info.’ 
16 Those forum users against the use of CJC-1295 advocated adherence to protein diets, use of 
17 
18 stimulant fat-burner supplements, and in a minority of postings the use of clenbuterol. Forum 
19 activity advocated user researching prior to deciding to purchase. Caution was advised on 
21 using CJC-1295. 
22 
23 ‘I can’t believe people want to supplement with this without adequate research.’ 
24 Female users observed concern for influences and pressures to use CJC-1295 by male 
26 trainers, boyfriends and husbands. Forum activity underscored the need for informed 
27 
28 decision-making based on personal research. 
29 ‘Most male trainers, boyfriends and husbands are sorting out your cycles. If you 
31 are getting your info from men, it's up to YOU to STILL do the research and know 
32 
33 the whats/whens/wheres of what you're putting in your body.’ 
34 Forum activity centred on user questioning around which CJC-1295 products to purchase, in 
36 terms of whether to purchase CJC-1295 with Drug Affinity Complex (DAC) or without. 
37 
38 Views varied on cost effectiveness and weekly dosing schedules. With DAC was reportedly 
39 more expensive. 
41 ‘I don't know which one. With DAC or without it. If with DAC, I just need to 
42 
43 inject it once a week, it will be cheaper.’ 
44 Some comments centred on CJC-1295 safety improved by DAC. 
46 ‘From what I have researched on DAC it makes compounds safer and more 
47 
48 effective. Drug affinity complex is basically supposed to make a compound more 
49 efficient with longer lasting effects.’ 
51 
52 
53 Consequences and risks of female use of CJC-1295 
54 Most forum posts appeared concerned with the consequences of use in females as opposed to 
56 males. This centred on CJC-1295 effects on muscle enhancement and contraception. 
57 
58 
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4 ‘Does anyone know the effects of CJC 1295 on women? Like I said I am only 
6 trying to lose weight and tone up, not bulk up.’ 
7 
8 Activity awareness of gender specific differences in growth hormone pulses between males 
9 and females also formed basis of discussions. 
11 ‘Women have more pulses throughout the day and higher troughs. Men have a 
12 
13 huge night-time pulse that results in most of their GH release for the day.’ 
14 Users speculated on the female risks of synthetic growth hormone use. Choices to use CJC- 
16 1295 and other products centred on preferential outcomes between products on the market. 
17 
18 Some awareness was evident in forum discussion on the risks on female use causing damage 
19 to the pituitary gland due to the over stimulation and secretion of human growth hormone. 
21 ‘CJC 1295 makes the body produce more growth hormone without shutting 
22 
23 natural production down. CJC increases growth hormone production tenfold 
24 which makes it very risky for women’. 
26 
27 
28 CJC-1295 poly pharming in female PIED repertoires 
29 Forum users for the most part appeared well versed and experienced in the use of a host of 
31 synthetic enhancement drug supplements. 
32 
33 ‘At 27  I can't say I've  seen  much  age  related  wear  and tear yet.  I'm  running  it 
34 primarily   for   the   synergistic   effects   with   anabolic,   and   injury   repair and 
36 prevention.’ 
37 
38 GHRP-6 (a specific product) was described as particularly useful stack along with CJC-1295. 
39 ‘CJC-1295 brings about persistent and chronically elevated levels of growth 
41 hormone while GHRP-6 if injected a couple of times a day amplifies the very 
42 
43 important GH pulses. The two compounds greatly complement each other.’ 
44 GHRP-6 was also advocated by some users for its effect on boosting appetite and reduction 
46 of inflammation and aiding soft tissue healing. Some users considered using CJC-1295 with 
47 
48 GHRP-2 (another available product), due to negative views on the GHRP6 associated intense 
49 appetite. 
51 ‘Be careful with the GHRP! It will make you extremely hungry! I am not kidding, 
52 
53 you will blow your diet in 30 min!’ 
54 Arginine an essential amino acid was viewed to improve fat loss, and improve the use of 
56 CJC-1295 in increasing the potency of the growth hormone spike. Other comments centred 
57 
58 on using glutamine to increase GH in the body, and stacking with IGF-1 LR3, a synthetic 
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4 peptide product purported to increase muscle growth and fat burning simultaneously and 
6 slower in delivery and release. 
7 
8 CJC-1295 female outcomes 
9 When using CJC-1295, salient outcomes centred on the improved sense of well-being and 
11 facilitated continued use. 
12 
13 ‘My  mood  is  1000%  improved,  in  particular,  my  outlook  and  attitude  have 
14 changed for the positive and my energy levels are better. My skin definitely has 
16 cleared up and my husband thinks I'm looking slimmer even though there really 
17 
18 hasn't been much exercise.’ 
19 One CJC-1295 user reported using alongside natural progesterone and topical testosterone in 
21 order to stave off menopause. 
22 
23 ‘Even if it was doing nothing physically I'd take it for the improved mental 
24 outlook alone’. 
26 Those using when not training and rehabilitating from injury reported satisfactory 
27 
28 experiences. 
29 ‘The primary reason for my beginning is anti-aging and injury (rehab). My joints 
31 generally feel a bit better. Shoulders and knees significantly less painful and I 
32 
33 just feel better overall.’ 
34 Acute side effects appeared to relate to the growth hormone pulse. Some users reported ‘flush 
36 and tightness’ feelings on using CJC-1295. 
37 
38 ‘Interestingly, I've started noticing my own natural "pulses" of growth hormone 
39 are becoming more pronounced (taking the shot, I know what they feel like now). 
41 I get one virtually the same time every day, right around 3:00 p.m. (so I'm 
42 
43 reasonably confident it's not a hot flush).’ 
44 One user reported elevated heart rate, and difficulty sleeping which contrasts with CJC-1295 
46 proponents of improved sleep. This was observed by other forum users to be caused by 
47 
48 underlying cortisol issues, with increased growth hormone release exacerbating insomnia. 
49 ‘Depending on the actual cause of the insomnia, increased GH release can 
51 actually make it worse. That was my experience. I felt like I'd had a double 
52 
53 espresso and the feeling lasted for HOURS.’ 
54 Some users reported on increased appetite toward certain foods when using CJC-1295. 
56 ‘Clearly the pulse is bigger now. I can control the hunger (barely) but I find I am 
57 
58 looking for something to eat often. I steer myself towards fibrous, relatively low 
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4 calorie foods in an attempt to fill  myself up.  It  doesn't  really work.  The hunger is 
6 pretty much constant. This does seem to trigger more hunger in women than men. 
7 
8 I notice I crave cholesterol heavier -- i.e., hormone building -- foods like butter, 
9 eggs and red meat lately.’ 
11 
12 
13 CJC-1295 protocols advocated by female users 
14 Posting in forum discussions around sourcing were minimal and in accordance with website 
16 rules, however several users mentioned delivery of shipments which indicated web 
17 
18 purchasing. Products were stored in fridges. Some comments were made around 
19 reconstitution with bacteriostatic water and lack of information around constitution protocols. 
21 1/2cc 28-30g insulin syringes were recommended. Preloading of syringes was not advised 
22 
23 due to loss of stability. Reconstitution by one user was recommended as follows; 
24 ‘To reconstitute put 1-2cc in the bottles. The CJC 1295 usually 
26 come in 2mg vial; 
27 
28 2000mcg/1cc: 20mcg/iu 
29 2000mcg/2cc: 10mcg/iu 
31 5000mcg/1cc: 50mcg/iu 
32 
33 5000mcg/2cc: 25mcg/iu 
34 Questions centred on CJC-1295 recommended dosage, effects, frequency of injecting, and 
36 optimal cycling. Dosage estimations were extrapolated from male guides and other growth 
37 
38 hormone peptides (1mcg/kg), and calculated per bodyweight in kilograms was advised. 
39 Tentative gauging of dosage was recommended. 
41 ‘For men and women the dose is the same .... 1.0 microgram/kg, which also turns 
42 
43 out to be the saturation level for most peptides. However, it is wise to start out 
44 with less and see how your body reacts before going up. Once you reach the 
46 saturation does, more is not better.’ 
47 
48 Subcutaneous injecting was advocated to occur prior to bedtime, and after eating. CJC-1295 
49 injecting outcomes appeared to relate to time of day when administered, with pre-bedtime 
51 advocated for fat loss and anti-aging purposes, and morning/pre training for muscle 
52 
53 enhancement. Site rotation was advised. 
54 ‘Your injection times must occur at times of natural growth hormone pulsation. 
56 You should not arbitrarily pick times of the day. Injection times in order of 
57 
58 greatest to least therapeutic effect are: bedtime, immediately post work out, 
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4 immediately upon rising. Any other time of the day the effect of the shot might be 
6 negligible.   GH  spikes  encourage   restful   sleep,  so   you   should  actually sleep 
7 
8 better.’ 
9 Discussions centred on the optimal forums of administration and cycling. Some users 
11 advocated a ‘4 on – 3 off schedule’. One user posted; 
12 
13 ‘I’ve been told that the "norm" is 1iu/day 5 days on 2 days off works well.’ 
14 CJC-1295 use of minimum six month continued use was advised in order to see good results. 
16 Long term cycles at lower dosages were advocated so as to achieve optimal anti-aging 
17 
18 results, despite awareness of damage to pituitary function. Long term use, in one instance 
19 eleven months, was observed to contribute to bloating and near constant joint pain. 
21 ‘CJC-1295 triggers an unnatural smaller, frequent pulse. Running CJC for 
22 
23 relatively short periods of time isn't a problem. It's running it long-term for anti- 
24 aging that can eventually cause pituitary problems.’ 
26 
27 
28 Discussion 
29 Reviews to date have underscored how athletes use growth hormone to assist recovery from 
31 sports injuries, and enhance performance (Erotokritou-Mulligan et al., 2011). Use of growth 
32 
33 hormone is common within poly substance taking repertoires of anabolic androgenic steroid 
34 users (Skarberg et al., 2009), and young male weight lifters, and associated with anabolic 
36 steroid and drug dependence (Brennan et al., 2011). Earlier studies have not found 
37 
38 differences in ethnicity, age or sport activity between adolescent users and non-users of 
39 human growth hormone, despite evidence for significant association between anabolic steroid 
41 and human growth hormone use (Rickert et al., 1992). Of interest for this study, is that Baker 
42 
43 et al., (2006) found increases in use of growth hormone for cosmetic reasons among health 
44 club attendees, with particular sourcing routes grounded in internet retail. This netnogaphic 
46 study garnered rich data in the under researched area of female enhancement drug use, and 
47 
48 the emerging trend of growth hormone used by women for anti-aging, lipolytic, and 
49 rehabilitation purposes (Kozinets, 2010). It presents a unique observation of textual discourse 
51 of female fora activity on public body building sites around the particular use of CJC-1295, 
52 
53 and yields insight into use of this synthetic analogue as per the realities of female users 
54 themselves. 
56 
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4 Use  of  enhancement  drugs  amongst  women  involved  in  recreational  fitness  training  and 
6 willingness to share opinions and information on the internet have been observed in recent 
7 
8 times, and are perhaps indicative of diffusion of drug enhancement supplements into more 
9 mainstream female groups interested to discover the world of image and performance 
11 enhancement. Similar to Jespersen (2012), a minority of posts were posted by male partners, 
12 
13 on behalf of interested wives and girlfriends. Research points to female body dissatisfaction, 
14 supplement use, unhealthy nutritional practices and weight control practices in bodybuilding 
16 (Goldfield,   2009). Gender differences are evident with female athletes reporting 
17 
18 preoccupation with physiques and greater concern with body fat, likelihood to restrict caloric 
19 intake, and use weight loss supplements (Gruber and Pope, 2000; Muller et al., 2009). 
21 
22 
23 Motivations to use growth hormone for these women centred on cosmetic shortcuts to obtain 
24 the ideal ‘sporting’ body (Hargreaves, 1994). Female forum users expressed extreme and 
26 personal interest in the use of CJC-1295 for image enhancement purposes centring on image 
27 
28 (the  attainment  of  muscle  enhancement,  fat  loss  and  youthful  skin). Similar to other 
29 netnographies investigating use of synthetic tanning peptides (Van Hout, 2014), the internet 
31 has become a medium for “sophisticated communal folk pharmacology” (Monaghan, 2001; 
32 
33 Skarberg  et   al.,   2009;  Smith   & Stewart,  2012). Within the cyber community, female 
34 interactions on bodybuilding forums potentially create personal and social normalisation of 
36 image and performance enhancement drug use in attaining hyper fit and youthful identities. 
37 
38 Such dynamic cyber activity fuels the expansion of self (and ‘selfing’) beyond physical 
39 limitations (Fernback, 2007; Robinson, 2007), and accelerates knowledge distribution (Smith 
41 & Stewart, 2012), in this instance around optimal poly pharming and potential interactions 
42 
43 with other growth hormone and fat burning supplements. Of interest was the lack of reference 
44 to online peptide calculators as was reported in an online study of the synthetic tanning 
46 peptide, Melanotan (Van Hout, 2014). 
47 
48 
49 Discussions  around  gender  specific  outcomes  relating  to  CJC-1295  centred  on deleterious 
51 health  implications  on  female  use,  despite  commitment  to  attainment  of  physical  ideals. 
52 
53 Awareness of the growth hormone pulse and gender variations in pulse activity (Van Cauter 
54 et al., 1997) complicated discussions and views around protocols for use of CJC-1295 and 
56 other synthetic analogues. Normal young adults have low growth hormone levels abruptly 
57 
58 interrupted by large secretory pulses (Van Cauter & Plat, 1996), with major pulses occurring 
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4 shortly after slow wave sleep onset (Takahashi et al., 1968; Sassin et al., 1969). According to 
6 Pritzlaff-Roy  et  al.,  (2002)  females  have  more  frequent  growth  hormone  secretory pulses, 
7 
8 greater basal (non-pulsatile) growth hormone secretion with greater secretory pulse 
9 amplitude, and greater mass of growth hormone secreted per pulse when compared with 
11 males. Growth hormone release at rest is also higher in young females (Van den Berg et al., 
12 
13 1996; Giustina & Veldhuis, 1998; Wideman et al., 1999) and is a result of a twofold greater 
14 mass of growth hormone secreted per burst in young women (Veldhuis et al., 1995; Van Den 
16 Berg et al, 1996). Users and prospective CJC-1295 users were aware of these implications for 
17 
18 the administration and cycling of CJC-1295. The advice not to use CJC-1295 and concentrate 
19 on diet and training (and similar to Jespersen, 2012) was observed and centred on lack of 
21 available knowledge around potential harms, particularly in the case of female use. Concerns 
22 
23 around long term use are grounded in risks for cardiomyopathy, hypertension, valve 
24 dysfunction, arrhythmias, diabetes mellitus and other adverse health consequences in use of 
26 GH (Colao et al., 2004; Matano et al., 2005; Jorgensen et al., 2007; Colao, 2008). 
27 
28 
29 Limitations 
31 Given the combination of self-reported experiences, discussion threads and potential for multiple 
32 
33 screen pseudonyms, it is not possible to provide a detailed representative profile of female CJC-1295 
34 users. We recognise that textual data garnered may be confounded by self-report issues, potential for 
35 
36 reliance on what is reported by female users accessing bodybuilding fora, and lack of 
37 verification of the CJC-1295 and other synthetic growth hormone analogues used. We also 
39 recognise that despite recording 59 distinct site pseudonyms after removal of duplicate 
40 
41 threads, we cannot be sure that multiple threads were generated by the same individuals. 
42 However, validity of the study is enhanced by the systematic manner by which we examined 
44 embedded, multi-level and multi sited online CJC-1295 phenomena (Wittel, 2000) and which 
45 
46 enhances ‘trustworthiness’ (Wallendorf & Belk, 1989) by virtue of verification of extensive 
47 similarities  across  female  fora  activity relating to  reasons  for use,  practices  and  outcomes. 
49 Secondly, validity in adhering to EPP protocols was grounded in our implementation of 
50 
51 partial phenomenological psychological reduction, horizontal consistency and vertical 
52 consistency in interpretation of the data (Karlsson, 1995). 
54 
55 
56 Conclusion 
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4 Increased  trend  interest  in  CJC-1295  and  other  synthetic  growth  hormone  analogues have 
6 occurred  in  line  with  recent  popularity of  controversial anti-aging medicine,  proliferation of 
7 
8 anti-aging products and enhancement drug supplementation and are increasingly driven by 
9 media and internet retail. Regrettably, the consequences of ‘cash only’ business in the web 
11 retailing, sale and purchase of CJC-1295 include the lack of reporting of adverse events, 
12 
13 product monitoring and overall pharmacovigilance. The study has implications for clinical 
14 screening and practice, due to the considerable overlap between the use of enhancement 
16 drugs and complications associated with dependence. Further research is warranted into the 
17 
18 neurobiology of growth hormone abuse so as to investigate long term effects and inform 
19 health professionals and users. Credible forms of health education tactics should accurately 
21 advise users of health risks, hazards associated with counterfeit products and illicit sourcing 
22 
23 of these supplements. Continued development of internet methodologies to improve 
24 indigenous harm reduction on sites with enhancement drug activity, and improved site 
26 surveillance for novel enhancement drug market entries, exposure of ideas, user perspectives 
27 
28 and user trends is warranted. 
29 
30 
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5 Tables 
6 
7 Table 1 Sites containing discussions around CJC-1295 and records remaining following application of exclusion criteria. 
9 
10 WEBSITE ADDRESS NAME OF WEBSITE Initial search 
11 result in female 
12 sections number 
13 of users 
14 reports/threads 
After exclusion due to: 
-No Females 
experiences/queries/discussi 
ons in thread 
-Duplicates 
Distinct pseudony 
site recorded 
15 1 www.anabolicminds.com Anabolic Minds 5 5 12 
16 2 http://www.eroids.com/ Eroids.com 0 0 0 
17 4 http://forums.steroidal.com/forum.php Steroidal.com 0 0 0 
18 5 http://www.uk-muscle.co.uk/forum.php UK-M 4 1 2 
20 6 http://www.bodybuilding.com/ Bodybuilding.com 1 1 4 
21 7 http://www.worldclassbodybuilding.com/forums/ World Class 
22 Bodybuilding 
1 0 0 
23 8 http://www.elitefitness.com/forum/ Elite Fitness 10 7 18 
24 9 http://www.anasci.org/vB/ Ana Sci 0 0 0 
25 10 http://www.ugbodybuilding.com/threads/11262- 
26 Bad-headaches-from-Cjc-1295-w-o-dac 
27 11 http://forums.rxmuscle.com/search.php?searchid= 28 1254629 
30 12 http://www.anabolic- 
31 enhancement.com/forum/index.php 
32 13 http://www.steroidology.com/forum/search.php?s 
33 earchid=3082462 
34 
UG Bodybuilding 1 1 3 
Rx Muscle Forum 3 1 4 
Peak Muscle 1 1 5 
Steroidology 11 6 11 
35 TOTALS: 37 23 59 
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5 Table 2 Categories and themes emerging during the empirical phenomenological psychological analysis method. 
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33 
34 
35 
36 
37 
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39 
40 
41 
42 
43 
44 
45 
46 URL: http:/mc.manuscriptcentral.com/lsum eincert@gmail.com 
47 
48 
49 
Theme Category 
Female interest in CJC-1295 and informed decision-making 1. Choices to use CJC-1295 centring on its properties to stimulate fat loss, 
enhance muscle tone, improve sleep, joint mobility, aid in healing and 
improve skin quality and texture. 
2. Queries on CJC-1295 on foot of media articles and both online and real peer 
feedback. 
3. Need for informed decision-making based on personal research. 
4. Caution advised on using CJC-1295. 
5. Those against the use of CJC-1295 advocated adherence to protein diets, use 
of stimulant fat-burner supplements, and in a minority of postings the use of 
clenbuterol. 
6. Concern for influences and pressures to use CJC-1295 by male trainers, 
boyfriends and husbands. 
7. Which CJC-1295 products to purchase, in terms of whether to purchase 
CJC-1295 with DAC or without. 
8. Views varied on cost effectiveness and weekly dosing schedules. 
9. With DAC reportedly more expensive. 
10. CJC-1295 safety improved by DAC. 
Consequences and risks of female use of CJC-1295 11. Female risks of growth hormone releasing peptides (GHRP) use - damage to 
the pituitary gland due to the over stimulation and secretion of human 
growth hormone.. 
12. Concern with the consequences of use in females as opposed to males (CJC- 
1295 effects on muscle enhancement and contraception). 
13. Activity awareness of gender specific differences in GH pulses between 
males and females. 
14. Choices to use CJC-1295 and other GHRP centred on GHRP use as 
alternative to GH use. 
15. Concerned husbands and partners. 
CJC-1295 poly pharming in female PIED repertoires 16. Well versed and experienced in the use of a host of GH releasing peptides. 
17. CJC-1295 considered within a repertoire of existing supplements used 
(HGH 176-191/HGH FRAG, GHRP2, GHRP6, Insulin Like Growth Factor 
(IGF-1 LR3; IGFI); Ipamorelin; injectable L-carnitine). 
18. GHRP6 described as particularly useful stack along with CJC-1295. 
19. GHRP6 advocated by some for its effect on boosting appetite and reduction 
of inflammation and aiding soft tissue healing. 
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 20. Some considered using CJC-1295 with GHRP-2, due to negative views on 
the GHRP6 associated intense appetite. 
21. Arginine an essential amino acid viewed to improve fat loss, and improve 
the use of GHRH in increasing the potency of the GH spike. 
22. Glutamine used to increase GH in the body 
23. Stacking with IGF-1 LR3, a synthetic peptide purported to increase muscle 
growth and fat burning simultaneously, and slower in delivery and release. 
CJC-1295 female outcomes 24. Salient CJC-1295 outcomes centred on the improved sense of wellbeing and 
facilitated continued use. 
25. One reported use alongside natural progesterone and topical testosterone in 
order to stave off menopause. 
26. Those using CJC-1295 when not training and rehabilitating from 
injury reported satisfactory experiences. 
27. Acute side effects appeared to relate to the GH pulse. 
28. Some reported ‘flush and tightness’ feelings on using CJC-1295. 
29. One reported elevated heart rate, and difficulty sleeping which contrasts 
with CJC-1295 proponents of improved sleep. 
30. Insomnia was observed to be caused by underlying cortisol issues, with 
increased GH release exacerbating insomnia. 
31. Some reported on increased appetite toward certain foods when using 
CJC-1295. 
CJC-1295 protocols advocated by female users 32. Posting in forum discussions around sourcing were minimal and in 
accordance with website rules. 
33. Several reported delivery of shipments which indicated web purchasing. 
34. CJC-1295 products were stored in fridges. 
35. Some comments were made around reconstitution with bacteriostatic water 
and lack of information around constitution protocols. 
36. 1/2cc 28-30g insulin syringes were recommended. 
37. Preloading of syringes was not advised due to loss of stability. 
38. Reconstitution advice was given. 
39. Questions centred on CJC-1295 recommended dosage, effects, frequency of 
injecting, and optimal cycling. 
40. Dosage estimations were extrapolated from male guides and other GH 
peptides (1mcg/kg), and calculated per bodyweight in kilograms. 
41. Tentative gauging of dosage was recommended. 
42. Subcutaneous injecting was advocated to occur prior to bedtime, and after 
eating. CJC-1295 injecting outcomes appeared to relate to time of day when 
administered, with pre-bedtime advocated for fat loss and anti-aging 
purposes, and morning/pre training for muscle enhancement. 
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 43. Site rotation was advised. 
44. Some advocated a ‘4 on – 3 off schedule’ 
45. CJC-1295 use of minimum 6 months continued use was advised in order to 
see good results. 
46. Long term cycles at lower dosages were advocated so as to achieve optimal 
anti-aging results, despite awareness of damage to pituitary function. 
47. Long term use, in one instance 11 months, was observed to contribute to 
bloating and near constant joint pain. 
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1 
2 
3 DAC Drug Affinity Complex: Drug affinity complex (DAC) technology optimises longer 
4 half-life and resultant therapeutic window of products. 
5 
6 Empirical   Phenomenological   Psychological   Method   (EPP):   a   scientific   approach   for 
7 exploring  and  describing  subjective  experiences  and  its  perceived  meaning.  The  analysis 
8 process emphasizes an open and bias-free attitude towards the data. 
10 
11 Netnography: the study of cultures and online communities emerging through computer- 
12 mediated communications. 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
URL: http:/mc.manuscriptcentral.com/lsum eincert@gmail.com 
  
Page 29 of 29 Substance Use and Misuse 
 
 
1 
2 
3 Author Names and Affiliations: 
4 Author 1: Dr Marie Claire Van Hout is the Coordinator, Substance Misuse Research, School of Health 
5 Sciences, Waterford Institute of Technology, which is registered on the European Network of  Centres for 
6 Pharmacoepidemiology and Pharmacovigilance (ENCePP) of the European Medicines Agency (EMA). Her 
7 research  interests include  new psychoactive  substances, performance  and  image  enhancement drugs, 
8 pharmaceutical misuse and internet drug monitoring. 
9 
10 
11 
12 
13 
14 
15 
16 
17 Author 2: Evelyn Hearne is a post graduate student of the MSc in Public Health at the Centre for Public 18 Health,   Liverpool   John   Moores   University,   United   Kingdom.   Her   research   interests   include new 19 psychoactive  substances,  performance  and  image  enhancement  drugs,  internet  drug  monitoring and 20 injecting drug use behaviours. 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
URL: http:/mc.manuscriptcentral.com/lsum eincert@gmail.com 
